<DOC>
	<DOCNO>NCT00129415</DOCNO>
	<brief_summary>The purpose investigation study effectiveness longer wavelength UVA1 ( 340-400nm ) short wavelength ultraviolet B [ UVB ] ( 290-320nm ) irradiation treatment inflammatory skin condition ( : atopic dermatitis , psoriasis , mycosis fungoides , alopecia areata , stretch mark urticaria ) . This research study aim evaluate effectiveness investigational device similar appearance `` tanning bed '' emits ultraviolet irradiation specific wavelength know UVA1 . This device approve Food Drug Administration ( FDA ) general use country , yet , use quite successfully Europe several year treat condition scleroderma , atopic dermatitis , urticaria pigmentosa skin condition . Instead UVA1 therapy , patient may receive ultraviolet radiation specific wavelength know UVB . UVA1 light long wavelength therefore low energy wavelength UVB . UVB light often light associate get sunburn since high level energy . UVB light use successfully treatment many skin condition .</brief_summary>
	<brief_title>Ultraviolet ( UVA UVB ) Light Therapy Treatment Inflammatory Skin Conditions</brief_title>
	<detailed_description>The purpose investigation study effectiveness longer wavelength UVA1 ( 340-400nm ) short wavelength UVB ( 290-320nm ) irradiation treatment inflammatory skin condition . Inflammatory dermatoses refer condition like atopic dermatitis ( eczema ) psoriasis circulate leukocyte ( T cell , neutrophil , monocyte ) infiltrate skin . The infiltrate cell may malignant phenotype mycosis fungoides ( cutaneous T cell lymphoma-CTCL ) . Up 50 patient one diagnosis related condition participate study . The affected area body treat UVA1 UVB 5 time per week 16 week . The UVA1 dose 130 J/cm2 . The maximum UVB dose 4000 mJ/cm2 . This UVA1 dose schedule safely use Germany treat patient atopic dermatitis , mycosis fungoides , granuloma annulare , scleroderma , urticaria pigmentosa . Subjects evaluate clinically baseline , week 1 , 2 , 4 , monthly interval . More frequent evaluation may require depend condition study . Paired skin biopsy may take involve uninvolved ( treat untreated ) area UV therapy .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Striae Distensae</mesh_term>
	<criteria>Ages : 1080 year Clinical diagnosis inflammatory dermatoses atopic dermatitis , psoriasis , mycosis fungoides , alopecia areata , urticaria . No disease state physical condition would impair evaluation test site . Willing able receive UVA1 UVB , direct protocol ; make evaluation visit ; follow protocol restriction . Signed , write , witness , informed consent form . Must live within reasonable drive distance Ann Arbor , Michigan , and/or able attend schedule appointment study . History photosensitivity ( development hive bump exposure light ) . UVA1 UVB irradiation hypersensitivity UVA1/UVB photoprovocation test . Pregnant nursing woman . Involved investigational study within previous 4 week . Presence bacterial superinfection . Taken oral therapy skin condition within last 4 week Topical steroid therapy within last 2 week History excessive scar formation keloid</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>UVA1</keyword>
	<keyword>UVB</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>alopecia</keyword>
	<keyword>mycosis fungoides ( CTCL )</keyword>
	<keyword>urticaria</keyword>
	<keyword>inflammatory dermatosis</keyword>
	<keyword>stretch mark</keyword>
</DOC>